Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer
Zachary A. Seymour,Albert J. Chang,Li Zhang,Neil Kirby,Martina Descovich,Mack Roach,I-Chow Hsu,Alexander Gottschalk +7 more
TL;DR: SBRT for prostate cancer appears well tolerated, with mostly transient low-grade toxicity, and patients with prostate volumes ≥50 mL should be counseled regarding the increased risk of moderate-grade genitourinary toxicity.
Journal ArticleDOI
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Fernanda G. Herrera,Fernanda G. Herrera,Massimo Valerio,Dominik Berthold,Thomas Tawadros,Jean-Yves Meuwly,Véronique Vallet,Petra Baumgartner,Anne-Christine Thierry,Berardino De Bari,Patrice Jichlinski,Lana E. Kandalaft,George Coukos,Alexandre Harari,Jean Bourhis +14 more
TL;DR: Iradiation of the whole prostate with 36.25 Gy in 5 fractions and dose escalation to 50 Gy to the DIN was tolerable and determined as the recommended phase 1b dose and has promising antitumor activity, which will be confirmed by the ongoing phase 2 part.
Journal ArticleDOI
SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
Matthew Bernetich,Matthew Bernetich,Caspian Oliai,Rachelle Lanciano,Rachelle Lanciano,Alexandra L. Hanlon,John Lamond,John Lamond,Stephen Arrigo,Stephen Arrigo,Jun Yang,Jun Yang,Michael Good,Jing Feng,Royce Brown,Bruce B. Garber,Michael Mooreville,Luther W. Brady,Luther W. Brady +18 more
TL;DR: The experience with SBRT for the primary treatment of localized prostate cancer demonstrates favorable efficacy and toxicity comparable to the results reported for IMRT in literature.
Journal ArticleDOI
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
Catherine E. Mercado,Marie-Adele Sorel Kress,Robyn A. Cyr,Leonard N. Chen,Thomas M. Yung,Elizabeth G. Bullock,Siyuan Lei,Brian T. Collins,Andrew N. Satinsky,K. William Harter,Simeng Suy,Anatoly Dritschilo,John H. Lynch,Sean P. Collins +13 more
TL;DR: A combination of IMRT with SBRT boost is well tolerated with minimal impact on prostate cancer-specific QOL, and biochemical control was favorable at 3-year follow-up.
Journal ArticleDOI
ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
Thomas Zilli,Marta Scorsetti,Daniel R. Zwahlen,Ciro Franzese,Robert Förster,Niccolò Giaj-Levra,Nikolaos Koutsouvelis,Aurélie Bertaut,Michel Zimmermann,Giuseppe D'Agostino,Filippo Alongi,Matthias Guckenberger,Raymond Miralbell +12 more
TL;DR: This is the first multicenter phase I/II trial assessing the efficacy and safety of a single-dose SBRT treatment for patients with localized prostate cancer and if positive, results of ONE SHOT may help to design subsequent phase III trials exploring the role of S BRT monotherapy in the exclusive radiotherapy treatment of localized disease.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more